Acerca de
TME-responsive multifunctional nanoparticles
Conventional nano-drug delivery systems based on a single therapeutic mechanism face inherent limitations in tumor accumulation and variable treatment responses. Our research introduces a multifunctional nanoplatform that integrates ROS-mediated chemodynamic therapy (CDT) with heat-induced photothermal therapy (PTT), aiming to overcome these challenges. This approach combines multi-reactive therapeutic mechanisms with precise targeting, highlighting its potential as a next-generation cancer treatment strategy. Furthermore, this platform can be expanded into a precision-tailored nanotherapeutic system applicable to various solid tumor models.
Development of lyophilized cancer cell vaccine
We developed a cancer cell vaccine by loading damage-associated molecular patterns (DAMPs) and pathogen-associated molecularpatterns (PAMPs) onto cancer cells through the treatment of chemotherapy and E. coli, followed by lyophilization with Cryoprotectant. The incorporation of DAMPs was verified by assessing changes in DAMP levels after chemotherapy treatment, while the optimal conditions for PAMP loading were established by evaluating the encapsulation efficiency and cell damage of cancer cell after treatment with E. coli at various MOI values.
Milk protein corona coated nanoparticle for oral administration
We develop an oral extracellular vesicle (EV) delivery platform by engineering the EV surface for gastrointestinal stability.
While EVs are highly biocompatible, oral administration is limited by acidic conditions, digestive enzymes, and mucus/epithelial barriers. To overcome this, we create protein-coated MSC-derived EVs, controlling soft/hard protein corona formation and using charge-engineered proteins to improve coating stability and intestinal interactions. Ultimately, we aim to establish a versatile oral EV nanoplatform that alleviates intestinal inflammation (e.g., IBD) and restores gut homeostasis.
Curcumin-metal nanomedicine for cancer therapy
We are developing an anticancer therapy based on the natural compound curcumin. Although curcumin has been reported to exhibit a wide range of anticancer effects, its poor stability and low bioavailability have limited its clinical application. To overcome these challenges, we conjugate curcumin with metal ions to enhance its chemical stability and biological activity, and further encapsulate it into nanoparticles for targeted delivery to tumor tissues. This nanoplatform not only strengthens the induction of cancer cell death but also ensures sustained drug retention in the body and effective tumor suppression, thereby addressing the limitations of conventional therapies.
FimH expressed E.coli in situ oral administration cancer vaccine
Development of an M cell–targeted oral cancer vaccine platform using engineered bacteria and an inducible expression system This study aims to develop a switch-based oral vaccine platform in which engineered bacteria are orally administered and antigen and targeting protein expression are induced at a desired time point using an external inducer. By incorporating FimH mediated M cell targeting, the platform is designed to enhance mucosal immune responses in the gut. In addition, inducible recombinant protein expression and in situ OMV production are utilized to promote effective anti-tumor immune responses and establish a next-generation oral immunotherapy strategy
Call
+82-02-961-0693
Location
Room B123, Department of Regulatory Sciences, College of Pharmacy, 26 Kyunghee-daero, Dongdaemun-gu, Seoul, 02447, Republic of Korea